CN1742003A - 3－甲氨基－1－(2－噻吩基)－1－丙酮及其制备和应用 - Google Patents

3－甲氨基－1－(2－噻吩基)－1－丙酮及其制备和应用 Download PDF

Info

Publication number
CN1742003A
CN1742003A CNA2004800026862A CN200480002686A CN1742003A CN 1742003 A CN1742003 A CN 1742003A CN A2004800026862 A CNA2004800026862 A CN A2004800026862A CN 200480002686 A CN200480002686 A CN 200480002686A CN 1742003 A CN1742003 A CN 1742003A
Authority
CN
China
Prior art keywords
thienyl
methylamino
acid salt
acetone
naphthyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004800026862A
Other languages
English (en)
Other versions
CN100432069C (zh
Inventor
R·斯特姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of CN1742003A publication Critical patent/CN1742003A/zh
Application granted granted Critical
Publication of CN100432069C publication Critical patent/CN100432069C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明涉及3－甲氨基－1－(2－噻吩基)－1－丙酮的制备及其用于制备药物(+)－(S)－N－甲基－3－(1－萘氧基)－3－(2－噻吩基)丙胺草酸盐(商标名为度洛西汀)的应用。

Description

3-甲氨基-1-(2-噻吩基)-1-丙酮及其制备和应用
本发明涉及3-甲氨基-1-(2-噻吩基)-1-丙酮的制备和应用。
氨基醇1(图1)[(1 S)-3-甲氨基-1-(2-噻吩基)-丙-1-醇]是药物((+)-(S)-N-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺草酸盐-商标名为度洛西汀(Duloxetine))制备中受欢迎的中间体。迄今为止，所使用的制备上述中间体的方法复杂且需要昂贵的、不稳定的试剂。此外，还需要技术复杂的色谱法制备纯的化合物。参考，例如，EP 273658 A1；Liu等，Chirality 2000，12(1)，26～29；Wheeler等，J.Labelled Comp.Radiopharm.1995，36(3)，213-23；US5362886、EP457559，Deeter等，Tet.Lett.1990，31(49)，7101-4；EP0650965；L.A.Sorbera，R.M.Castaner，J.Castaner，Drugs of the Future2000，25(9)：907～916。
因此，本发明的目的在于提供更简单经济的方法制备度洛西汀。
本发明描述了一种新颖的、经济的获得异构(isomerically)纯的化合物1的方法。本发明方法采用新的酮5(图1)[3-甲氨基-1-(2-噻吩基)-1-丙酮]作为各方法共有的中间体，所述酮5通过对映选择性(enantioselective)还原可制得氨基醇1。氨基醇1随后生成度洛西汀的反应已为技术人员所熟知，并可以类似于EP0457559A2中所述的方法(与1-氟代萘反应)进行。
本发明涉及3-甲氨基-1-(2-噻吩基)-1-丙酮(图1，化合物5)及其酸加成盐。化合物5的酸加成盐是化合物5与无机酸或有机酸反应的产物。就上述目的而言，特别适用的酸有盐酸、硫酸、磷酸、草酸、富马酸、马来酸和乙酸。
制备酮5或氨基醇1的原料化合物可为噻吩或2-乙酰基噻吩。图1描述了制备酮5的三种路线(路线1～3)，如下所述：
路线1
化合物4由乙酰基噻吩、甲醛和二甲胺通过经典的曼尼希反应(Mannich reaction)制得(EP0457559A2，实施例1)。  单甲氨基酮5由制得的4与过量的甲胺通过逆迈克尔/迈克尔反应(Michaelreaction)制得。
路线2
化合物6由乙酰基噻吩、甲醛和甲胺通过经典的曼尼希反应制得(Blicke；Burckhalter；JACSAT；J.Amer.Chem.Soc.；64；1942；451，453)。单甲氨基酮5由制得的6与过量的甲胺通过逆迈克尔/迈克尔反应制得。
路线3
化合物7由噻吩8与3-氯丙酰氯通过经典的弗瑞德-克来福酰化作用(Friedel-crafts acylation)制得(如El-Khagawa，Ahmed M.；El-Zohry，Maher F.；Ismail，Mohamed T.；PREEDF；Phosphorus Sulfur；EN；33；1987；25～32所述)。单甲氨基酮5由7与甲胺反应制得。
本发明还涉及3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐制备外消旋形式或对映异构(enantiomerically)纯形式的N-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺或其酸加成盐的应用。特别优选制备(+)-(S)-N-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺草酸盐(度洛西汀)的应用。
本发明还涉及制备外消旋形式、或优选对映异构纯形式的N-甲基-3-(1-萘氧基)-3-(2-噻吩基)-丙胺或其酸加成盐的方法，所述方法首先制备3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐作为中间体，然后将所述中间体还原为相应的醇。
所述还原可在外消旋条件下或对映选择性地进行。优选对映选择性还原，特别是生成的产物为(S)-对映异构体1的还原。
所述还原可使用经典的对映选择性氢化方法化学方式实现，或者使用含有过渡金属的氢化催化剂或使用酶还原作用实现，所述氢化方法使用例如具有手性配体的NaBH4或LiAlH4以获得对映选择性，所述酶还原作用使用例如微生物脱氢酶，特别是细菌或真菌脱氢酶。
实验：
路线1：
首先在25ml的乙醇中引入5g盐酸盐形式的二甲氨基酮4，然后逐滴加入20当量的甲胺(40％，于水中)并在60～70℃搅拌混合物6小时。反应结束后，除去部分乙醇，即得到白色结晶固体状的产物5(产量为3.45g的盐酸盐)。
路线2：
首先在25ml的乙醇中引入5g盐酸盐形式的二酮6，然后逐滴加入20当量的甲胺(40％，于水中)并在70～80℃搅拌混合物6小时。反应结束后，除去部分乙醇即得到白色结晶固体状的产物5(产量为3.87g的盐酸盐)。
路线3：
首先在25ml的THF中引入5g氯代酮7，然后逐滴加入20当量的甲胺(40％，于水中)并在30～40℃搅拌混合物6小时。反应结束后，移除大部分THF并分离出白色结晶固体状的产物5(产量为4.10g的盐酸盐)。
在路线1～3中，甲胺水溶液还可用气态或液化的甲胺代替。
盐酸盐形式的单甲氨基酮5的光谱数据如下：
13C NMR(D2O，125MHz)自旋回波的峰裂数示于括号中：
δ(ppm)＝188.5(s)，140.4(s)，139.2(d)，137.8(d)，131.9(d)，46.9(t)，37.3(t)，36.0(q)
1H NMR(D2O，500MHz)：
δ(ppm)＝8.00(m，1H)，7.95(m，1H)，7.25(m，1H)，3.40(m，2H)，2.75(m，2H)，2.62(s，3H)
还原化合物5以生成化合物1(图1)
NaBH4(外消旋)：
首先在20ml的乙醇中引入5g甲氨基酮5，然后在20℃下分批加入0.8当量的NaBH4。混合物搅拌6小时后用水进行后处理。得到淡黄色固体状的外消旋单甲氨基醇1(产量为3.9g)
1H NMR(500MHz，CDCl3)
δ(ppm)＝2.1(m，2H)，2.5(s，3H)，2.9(m，2H)，4.5(br s，2H)，5.25(m，1H)，6.94(m，1H)，7.00(m，1H)，7.22(m，1H)
13-C-NMR(125MHz，CDCl3)
δ(ppm)＝35.4，36.3，49.7，71.4，122.5，123.8，126.6，149.3
采用LiAlH4(手性修饰的)的方法如EP 0457559A2，实施例1B中所述的(对映选择性地)进行。
1的产率为74％，对映异构的纯度为72％ee。

Claims (8)

1.3-甲氨基-1-(2-噻吩基)-1-丙酮及其酸加成盐。
2.3-甲氨基-1-(2-噻吩基)-1-丙酮盐酸盐。
3.3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐用于制备N-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺或其酸加成盐的应用。
4.根据权利要求3的应用，用于制备(+)-(S)-N-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺草酸盐(度洛西汀)。
5.根据权利要求3的应用，其中3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐还原为(1S)-3-甲氨基-1-(2-噻吩基)-丙-1-醇或其酸加成盐。
6.一种制备(+)-(S)-N-甲基-3-(1-萘氧基)-3-(2-噻吩基)-丙胺草酸盐(度洛西汀)的方法，其中3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐作为中间体制备。
7.根据权利要求6的方法，其中3-甲氨基-1-(2-噻吩基)-1-丙酮或其酸加成盐还原为(1S)-3-甲氨基-1-(2-噻吩基)-丙-1-醇或其酸加成盐。
8.根据权利要求7的方法，其中还原作用采用微生物脱氢酶进行。
CNB2004800026862A 2003-01-22 2004-01-15 3-甲氨基-1-(2-噻吩基)-1-丙酮及其制备和应用 Expired - Fee Related CN100432069C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10302595.2 2003-01-22
DE10302595A DE10302595A1 (de) 2003-01-22 2003-01-22 3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung

Publications (2)

Publication Number Publication Date
CN1742003A true CN1742003A (zh) 2006-03-01
CN100432069C CN100432069C (zh) 2008-11-12

Family

ID=32602896

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800026862A Expired - Fee Related CN100432069C (zh) 2003-01-22 2004-01-15 3-甲氨基-1-(2-噻吩基)-1-丙酮及其制备和应用

Country Status (10)

Country Link
US (1) US7259264B2 (zh)
EP (1) EP1587802B1 (zh)
JP (1) JP4837552B2 (zh)
KR (1) KR101070977B1 (zh)
CN (1) CN100432069C (zh)
AT (1) ATE378326T1 (zh)
CA (1) CA2513542C (zh)
DE (2) DE10302595A1 (zh)
ES (1) ES2294457T3 (zh)
WO (1) WO2004065376A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912582A (zh) * 2020-07-10 2022-01-11 南京桦冠生物技术有限公司 度洛西汀中间体的制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044049A2 (en) 2006-07-03 2009-04-08 Ranbaxy Laboratories Limited Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine
ATE552250T1 (de) 2006-12-22 2012-04-15 Synthon Bv Verfahren zur herstellung von duloxetin und verwandten verbindungen
US8168805B2 (en) * 2007-10-29 2012-05-01 Sci Pharmtech, Inc Optically active methylhydroxylaminopropanol compound and its use as intermediate for preparation of (S)-(−)-3-methylamino-1-(2-thienyl)propan-1-ol
US7829731B2 (en) * 2007-10-29 2010-11-09 Sci Pharmtech, Inc. Methylhydroxylaminopropanol derivative and its use as intermediate for preparation of 3-methylamino-1-(2-thienyl)propan-1-OL
WO2009147687A2 (en) * 2008-06-03 2009-12-10 Shodhana Laboratories Limited An improved process for the separation of enantiomerically pure compounds
SI2329013T1 (sl) 2008-08-27 2016-03-31 Codexis, Inc. Polipeptidi ketoreduktaze za proizvodnjo 3-aril-3-hidroksipropanamina iz 3-aril-3-ketopropanamina
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011128370A1 (en) 2010-04-13 2011-10-20 Krka, D.D., Novo Mesto Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
ES2425379T3 (es) 2010-08-30 2013-10-15 Saltigo Gmbh Procedimiento para la preparación de (S)-3-N-metilamino-1-(2-tienil)-1-propanol
CN103214452B (zh) * 2013-05-07 2014-08-06 浙江丽晶化学有限公司 N-甲基-3-羟基-3-（2-噻吩基）-丙胺的制备方法
CN111793056A (zh) * 2020-07-27 2020-10-20 广州康瑞泰药业有限公司 一种度洛西汀中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5057339A (en) * 1988-12-29 1991-10-15 Matsushita Electric Industrial Co., Ltd. Metallized polyacetylene-type or polyacene-type ultralong conjugated polymers and process for producing the same
CA2042346A1 (en) 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
EP0571685A1 (en) * 1992-05-27 1993-12-01 Novo Nordisk A/S Aryloxyheteroarylpropylamines, their preparation and use
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE60329640D1 (de) 2002-07-09 2009-11-19 Lonza Ag Verfahren zur Herstellung von N-Monoalkyl-Beta-Aminoalkoholen
DE10240026A1 (de) * 2002-08-27 2004-03-11 Merck Patent Gmbh Verfahren zur Herstellung von Monoalkylaminoketonen
RU2340594C2 (ru) * 2002-08-27 2008-12-10 Мерк Патент Гмбх Способ энантиоселективного гидрирования аминоспиртов

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912582A (zh) * 2020-07-10 2022-01-11 南京桦冠生物技术有限公司 度洛西汀中间体的制备方法

Also Published As

Publication number Publication date
ES2294457T3 (es) 2008-04-01
US20060128791A1 (en) 2006-06-15
CN100432069C (zh) 2008-11-12
DE10302595A1 (de) 2004-07-29
KR20050098253A (ko) 2005-10-11
EP1587802A1 (de) 2005-10-26
JP4837552B2 (ja) 2011-12-14
CA2513542A1 (en) 2004-08-05
WO2004065376A1 (de) 2004-08-05
EP1587802B1 (de) 2007-11-14
CA2513542C (en) 2012-01-03
JP2006515878A (ja) 2006-06-08
ATE378326T1 (de) 2007-11-15
DE502004005491D1 (de) 2007-12-27
KR101070977B1 (ko) 2011-10-06
US7259264B2 (en) 2007-08-21

Similar Documents

Publication Publication Date Title
CN1742003A (zh) 3－甲氨基－1－(2－噻吩基)－1－丙酮及其制备和应用
CN1067681C (zh) (s)－(+)－n,n－二甲基－3－(1－萘基氧基)－3－(2－噻吩基)丙胺的制备方法
EP2114912B1 (en) Process for making duloxetine and related compounds
EP1478641A1 (en) Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
AU2005215906C1 (en) Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
Sakai et al. Resolution of 3-(methylamino)-1-(2-thienyl) propan-1-ol, a new key intermediate for duloxetine, with (S)-mandelic acid
WO2004031168A2 (en) Processes and intermediates for the preparation of optically active 3-amino-1-(2-thienyl)-1-propanol derivatives
US20050272930A1 (en) Process for the prepation of 3-hydroxy-(2-thienyl)propanamines
US8420832B2 (en) Optically active methylhydroxylaminopropanol derivative and its use as intermediate for preparation of (S)-(-)-3-methylamino-1-(-2-thienyl)propan-1-ol
US7829731B2 (en) Methylhydroxylaminopropanol derivative and its use as intermediate for preparation of 3-methylamino-1-(2-thienyl)propan-1-OL
US20100280093A1 (en) Process for the preparation enantiomerically pure salts of n-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine
CN1785959A (zh) N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
CN117645597A (zh) 不对称形式氢胺化合成度洛西汀的关键手性中间体的方法
CN1891682A (zh) 一种制备3－芳氧基－3－芳基丙胺的方法
WO2008078124A1 (en) A process for the preparation of duloxetin and new key intermediates for use therein
JP5830245B2 (ja) 光学活性のメチルヒドロキシルアミノプロパノール化合物を中間体として用いる（ｓ）−（＋）−ｎ−メチル−３−（１−ナフチルオキシ）−３−（２−チエニル）プロピルアミンの製造方法
EP2228372A1 (en) Process for Preparing (S)-(+)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl-Propylamine by using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate
WO2011077443A1 (en) An improved process for the preparation of duloxetine hydrochloride
KR20160044117A (ko) 광학 활성 3-클로로-1-아릴프로판-1-올 유도체로부터 3-아미노-1-아릴프로판-1-올 유도체의 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081112

Termination date: 20200115

CF01 Termination of patent right due to non-payment of annual fee